GleamWall
中文EN

BMEA Biomea Fusion, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840439 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY76.7%
TTM EPS YoY95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-192.3%
ROA-53.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.0%
Debt / equity0.00x
Current ratio2.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.98x
Accruals ratio52.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue————————
R&D expense$8.53M$9.14M$9.12M$8.12M$14.40M$16.57M$22.90M$25.24M
SG&A expense$4.43M$3.62M$3.65M$3.60M$4.20M$4.71M$6.82M$4.83M
Operating income-$12.96M-$12.77M-$12.77M-$11.72M-$20.80M-$21.28M-$29.71M-$30.07M
Net income-$6.18M-$8.33M-$12.41M$4.61M-$16.41M-$20.74M-$29.26M-$29.30M
EBITDA-$12.95M-$12.75M-$12.73M-$11.67M-$20.41M-$20.78M-$29.24M-$29.61M
EPS (basic)-0.09-0.12-0.17—-0.27-0.51-0.80-0.81
EPS (diluted)-0.09-0.12-0.17—-0.27-0.51-0.80-0.81
Weighted avg. shares (diluted)72.59M72.36M72.30M—59.85M40.63M36.63M36.27M
Banking
Net interest income$267,000$319,000$430,000-$3.53M$526,000$309,000$450,000$772,000
Balance sheet
Cash & equivalents$26.40M$34.82M$44.69M$55.81M$46.64M$56.22M$35.86M$58.65M
Current assets$27.66M$36.43M$46.32M$58.05M$49.44M$64.66M$44.69M$68.33M
PP&E, net$37,000$47,000$47,000$153,000$200,000$2.83M$3.30M$3.77M
Total assets$28.10M$36.87M$46.38M$58.57M$55.19M$73.16M$55.05M$79.94M
Current liabilities$12.77M$10.48M$9.29M$11.10M$15.56M$17.57M$19.82M$21.67M
Total liabilities$20.51M$24.74M$27.67M$29.02M$39.57M$45.65M$26.32M$28.36M
Shareholders' equity$7.59M$12.14M$18.72M$29.55M$15.62M$27.51M$28.74M$51.57M
Shares outstanding72.68M72.48M72.30M72.30M59.51M58.13M37.57M36.31M
Cash flow statement
Operating cash flow-$8.43M-$10.03M-$11.67M-$13.94M-$11.55M-$19.21M-$25.67M-$30.00M
Capital expenditure————$0$0$0$82,000
Free cash flow————-$11.55M-$19.21M-$25.67M-$30.09M
Investing cash flow$0$0$550,000—$0$0$0-$82,000
Financing cash flow$12,000——$23.11M$1.97M$39.57M$3.25M$413,000
Depreciation & amortization$10,000$20,000$46,000$47,000$400,000$500,000$468,000$469,000
Stock-based compensation$1.62M$1.59M$1.58M$1.84M$1.94M$2.57M$3.17M$4.49M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.